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Effect of pH on the In Vitro Activities of Amphotericin B,
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The in vitro susceptibilities of 21 Aspergillus isolates were tested against three antifungal agents in RPMI
1640 and yeast nitrogen base at pH 5.0 and 7.0 by a broth microdilution format of the NCCLS method. The
MICs of amphotericin B and itraconazole were higher, while those of flucytosine were lower, at pH 5.0 than at
pH 7.0. The poor correlation between in vitro results and clinical outcome could be due to a difference in pH
between the in vitro susceptibility test and at the site of infection.
In vitro susceptibility testing of filamentous fungi has be-
come increasingly important. A good standard in vitro suscep-
tibility test must give reproducible results, predict the resis-
tance of molds, and correlate with clinical outcome (5).
In 1998 the National Committee for Clinical Laboratory
Standards (NCCLS) proposed a standard method for the de-
termination of the in vitro antifungal susceptibility of conidi-
um-forming filamentous fungi. This document is now approved
(3). Although the standardized NCCLS method has been
found to give better inter- and intracenter reproducibility, in
vitro antifungal susceptibility testing of filamentous fungi is still
faced with several problems such as the correlation of in vitro
results with clinical outcome.
Clinical outcome may be affected by various factors related
to the host, the drugs, the fungus, and their interactions (9).
These factors are not taken into account in the in vitro tests,
and it may be for this reason that the prediction of antifungal
efficacy or failure from in vitro susceptibility tests remains
difficult. One of the host-related-factors is the pH at the site of
infection. In the human body the pH is carefully regulated at
7.4, but it may be lower at the site of infection due to necrosis
(7), the production of organic acids by fungi (6), or lysosome
activity of granulocytes and macrophages (1).
The aim of this study was to investigate the effect of pH on
the in vitro activities of three different antifungal agents
against 21 Aspergillus isolates in two different media.
Twenty-one clinical Aspergillus isolates were tested: five itra-
conazole (ITZ)-susceptible and five ITZ-resistant Aspergillus
fumigatus isolates, five A. flavus isolates, and six A. terreus
isolates. Isolates had been frozen in glycerol broth at 80°C;
they were revived by subculturing twice on Sabouraud glucose
agar tubes supplemented with 0.5% chloramphenicol and were
incubated for 5 to 7 days at 35°C. All isolates were tested in
duplicate on different days.
Candida parapsilosis ATCC 22019 and C. krusei ATCC 6258
were used for quality control. Amphotericin B (AMB; Bristol-
Myers Squibb, Woerden, The Netherlands), ITZ (Janssen
Pharmaceutica B.V., Tilburg, The Netherlands), and flucyto-
sine (5FC; ICN Pharmaceuticals, Zoetermeer, The Nether-
lands) were obtained as powders. AMB and ITZ were dis-
solved in dimethyl sulfoxide, and 5FC was dissolved in distilled
water. The final concentrations of the antifungal agents at pH
5.0 ranged from 256 to 0.25 g/ml for AMB, from 16 to 0.016
g/ml for ITZ, and from 1,024 to 0.001 g/ml for 5FC in both
yeast nitrogen base (YNB) and RPMI 1640. At pH 7.0 the final
concentrations ranged from 16 to 0.016 g/ml for AMB and
ITZ and from 1,024 to 0.001 g/ml for 5FC in YNB, and in
RPMI 1640 they ranged from 16 to 0.016 g/ml for AMB and
ITZ and from 256 to 0.25 g/ml for 5FC.
Drug dilutions were made in RPMI 1640 medium with L-
glutamine but without bicarbonate (GIBCO BRL, Life Tech-
nologies, Woerden, The Netherlands) and in YNB (DIFCO
Laboratories, Sparks, Md.). Both media were prepared accord-
ing to the manufacturers’ instructions and buffered to pH 5.0
with 10 mM citrate buffer or to pH 7.0 with 0.165 M 3-[N-
morpholino]propanesulfonic acid (MOPS) (Sigma-Aldrich
Chemie GmbH, Steinheim, Germany).
Susceptibility was tested by a broth microdilution method
according to NCCLS guidelines (M38-A) (3). Aliquots (100 l)
of the drugs at twice the targeted final concentration were
dispensed in the wells of flat-bottom 96-well microtiter plates
(Costar, Corning, N.Y.). Conidial suspensions were prepared
spectrophotometrically and were further diluted in medium. In
order to obtain a final inoculum concentration of 0.4  104 to
5  104 CFU/ml, 100 l of the inoculum was added to the
wells. The microtiter plates were incubated at 35°C for 48 h.
After 48 h, growth was assessed spectrophotometrically with
a microplate reader (Anthos htIII; Anthos Labtec Instruments,
Salzburg, Austria) at 405 nm. For AMB and ITZ the lowest
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concentration that showed no growth in comparison to that of
the growth control (MIC-0), and for 5FC the lowest concen-
tration that showed no more than 50% growth in comparison
with that of the growth control (MIC-2), was taken as the MIC
end point (3).
Results were analyzed by the Mann-Whitney test, and dif-
ferences were considered statistically significant at a P value of
0.01.
At pH 7.0 the susceptibilities of the two quality control
strains against the three tested antifungal agents were within
the recommended limits of the NCCLS in both media. At pH
5.0, however, the MICs of both AMB and ITZ were higher
than those at pH 7.0, whereas the MICs of 5FC were lower.
This result was independent of the medium used.
Table 1 shows the MICs of all three antifungal agents in both
media at pH 5.0 and 7.0. There was a significant difference
between the MICs found in RPMI 1640 versus YNB when
testing was conducted at either pH 5.0 or 7.0. In most cases the
MICs found in YNB were higher than those in RPMI 1640.
There was also a significant difference between the MICs
found at pH 5.0 versus 7.0 for both AMB and 5FC for all
species tested. For ITZ there was a significant difference for
some data sets of the ITZ-susceptible A. fumigatus isolates, the
A. flavus isolates, and the A. terreus isolates. No significant
difference was found for the ITZ-resistant A. fumigatus iso-
lates. The difference was independent of the medium used but
dependent on the antifungal agent tested. Figure 1 shows the
effect of pH on the in vitro activities of AMB, ITZ, and 5FC
against an A. flavus isolate in both media. In general, the in
vitro activities of both AMB and ITZ decreased when the
medium pH was lowered, while for 5FC the in vitro activity
increased when the medium pH was lowered. Dramatic
changes in the MIC were observed for both AMB and 5FC.
For AMB, MICs below 1 g/ml at pH 7.0 increased to 8
g/ml at pH 5.0, above the concentrations achievable in vivo.
The reverse was found for 5FC, where for most isolates high
MICs at pH 7.0 converted to very low MICs at pH 5.0, below
concentrations achievable in vivo.
These results were in agreement with results found in a
limited number of other studies in which the effect of pH on
antifungal activity was also investigated. Both Minagawa et al.
(2) and Odds et al. (4) showed that the in vitro activity of the
imidazole ketoconazole against yeast isolates decreased when
the medium pH decreased. Odds et al. also showed that for
yeast isolates the activity of AMB decreased and that of 5FC
increased when the medium pH decreased. The increase in
activity for 5FC was also found by Viviani et al. for Cryptococ-
cus neoformans (8). The mechanism that causes pH-dependent
change of activity of these antifungal agents is not clear and
warrants further study.
Buffered medium at a pH of 7.0 has been accepted as the
standard for in vitro susceptibility testing of microorganisms.
However, it is not yet clear that this is the optimal pH with regard
to clinical outcome. In a patient the pH at the site of a fungal
infection may very well be lower than the natural body pH of 7.4
due to necrosis (7), the production of organic acids by the fungus
(6), or lysosome activity of granulocytes and macrophages (1). For
this reason, it may very well be that the in vitro antifungal activity
found at pH 5.0 corresponds better with clinical outcome than the
in vitro activity found at the standard pH of 7.0. Considering our
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results, this means that for the treatment of invasive fungal infec-
tions it would be better to use 5FC or ITZ instead of AMB,
because both of the former drugs show better in vitro activities at
pH 5.0 than AMB. Further in vivo studies are necessary in order
to determine the pH at the site of infection and to correlate in
vitro results with in vivo response.
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